190 related articles for article (PubMed ID: 18592003)
21. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.
Bektas N; Haaf At; Veeck J; Wild PJ; Lüscher-Firzlaff J; Hartmann A; Knüchel R; Dahl E
BMC Cancer; 2008 Feb; 8():42. PubMed ID: 18254960
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
23. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.
Bilous M; Ades C; Armes J; Bishop J; Brown R; Cooke B; Cummings M; Farshid G; Field A; Morey A; McKenzie P; Raymond W; Robbins P; Tan L
Breast; 2003 Apr; 12(2):92-8. PubMed ID: 14659337
[TBL] [Abstract][Full Text] [Related]
24. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
[TBL] [Abstract][Full Text] [Related]
25. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues.
Wilson KS; Roberts H; Leek R; Harris AL; Geradts J
Am J Pathol; 2002 Oct; 161(4):1171-85. PubMed ID: 12368191
[TBL] [Abstract][Full Text] [Related]
26. Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours.
Paiva CE; Drigo SA; Rosa FE; Moraes Neto FA; Caldeira JRF; Soares FA; Domingues MAC; Rogatto SR
Ann Oncol; 2010 Apr; 21(4):734-740. PubMed ID: 19914962
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
29. Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression.
Stricker TP; Brown CD; Bandlamudi C; McNerney M; Kittler R; Montoya V; Peterson A; Grossman R; White KP
PLoS Genet; 2017 Mar; 13(3):e1006589. PubMed ID: 28263985
[TBL] [Abstract][Full Text] [Related]
30. Rhomboid domain containing 2 (RHBDD2): a novel cancer-related gene over-expressed in breast cancer.
Abba MC; Lacunza E; Nunez MI; Colussi A; Isla-Larrain M; Segal-Eiras A; Croce MV; Aldaz CM
Biochim Biophys Acta; 2009 Oct; 1792(10):988-97. PubMed ID: 19616622
[TBL] [Abstract][Full Text] [Related]
31. Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles.
Klopfleisch R; Lenze D; Hummel M; Gruber AD
BMC Cancer; 2010 Nov; 10():618. PubMed ID: 21062462
[TBL] [Abstract][Full Text] [Related]
32. Relationship between p53 and p27 expression following HER2 signaling.
Casalini P; Iorio MV; Berno V; Bergamaschi A; Børresen Dale AL; Gasparini P; Orlandi R; Casati B; Tagliabue E; Ménard S
Breast; 2007 Dec; 16(6):597-605. PubMed ID: 17604627
[TBL] [Abstract][Full Text] [Related]
33. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
[TBL] [Abstract][Full Text] [Related]
34. Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
Moatter T; Aban M; Iqbal W; Azam I; Pervaiz A; Siddiqui F; Murad F; Pervez S
Asian Pac J Cancer Prev; 2011; 12(11):3069-73. PubMed ID: 22393991
[TBL] [Abstract][Full Text] [Related]
35. HER2 expression in Brazilian patients with estrogen and progesterone receptor-negative breast carcinoma.
Ramalho S; Serra KP; Vassallo J; Soares FA; Pinto GA; Teixeira LC; da Cunha IW; Derchain SF; de Souza G
Acta Histochem; 2013 Mar; 115(2):120-7. PubMed ID: 22647460
[TBL] [Abstract][Full Text] [Related]
36. Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21(waf1) and p27(kip1).
Kalemi TG; Papazisis KT; Lambropoulos AF; Voyatzi S; Kotsis A; Kortsaris AH
Anticancer Res; 2007; 27(2):913-20. PubMed ID: 17465220
[TBL] [Abstract][Full Text] [Related]
37. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
38. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
39. Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.
Fitzgibbons PL; Murphy DA; Dorfman DM; Roche PC; Tubbs RR;
Arch Pathol Lab Med; 2006 Oct; 130(10):1440-5. PubMed ID: 17090184
[TBL] [Abstract][Full Text] [Related]
40. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
